viewEmerald Clinics Ltd

Emerald Clinics telehealth service supports patient appointments during pandemic

The company believes there is potential to extend its real-world evidence (RWE) platform to support the growing need to monitor COVID-19 patients.

Emerald Clinics Ltd - Emerald Clinics Telehealth service supports patient appointments during pandemic
Around 80% of recent appointments have been via telehealth

Emerald Clinics Ltd (ASX:EMD) reports that business has remained stable despite the restrictions being enforced across Australia due to COVID-19, with the patient count continuing to grow, referrals remaining steady and around 80% of recent appointments completed via telehealth.

The company plans to extend its real-world evidence (RWE) platform, which it believes could support the growing need to monitor COVID-19 patients and those self-isolating.

Emerald managing director and chief executive officer Dr Michael Winlo said: “Our team has been working quickly to extend our RWE platform so we can help address the COVID-19 pandemic for Australian patients and citizens.

“Emerald has unique resources such as a team of research focussed clinicians, a RWE platform and a Telehealth service that can respond to the circumstances.

“We look forward to exploring this further with several interested parties.”

Telehealth services

Considering the COVID-19 challenges, the company has implemented numerous measures to keep both staff and patients safe, while developing and expanding telehealth services.

In addition to simply engaging with a patient over the phone or video conference, the Emerald telehealth service can integrate remote patient health monitoring tools, patient medical records, medication management and other data gathering tools, that provide a much richer and more useful suite of information for the patient and the care giver.

The service is available for all consultations, while still allowing Emerald to gather key real-world data from its patients.

Health system support

Emerald's RWE platform can help support the growing need to monitor patients diagnosed with COVID-19 and those required to self-isolate by improving the understanding of what symptoms and other clinical risk factors are most relevant to assist rapid patient triage patients and help reduce unnecessary strain on the hospital system.

The company believes its system can help test and monitor several novel therapies and care approaches that are being trialled globally to assist patients in the absence of a vaccine for COVID-19.

To date, these initial approaches remain incomplete and confidential and the company notes that there is no guarantee that such approaches will evolve into binding agreements.

Emerald notes however, that the current COVID-19 situation is dynamic and subject to change.

Quick facts: Emerald Clinics Ltd

Price: 0.084 AUD

Market: ASX
Market Cap: $17.76 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emerald Clinics Ltd named herein, including the promotion by the Company of Emerald Clinics Ltd in any Content on the Site, the Company...


Emerald Clinics makes first big move into UK with Spectrum Biomedical deal

Emerald Clinics Ltd (ASX:EMD) CEO Dr Michael Winlo talks to Proactive about his company’s new partnership with Spectrum Biomedical UK to develop a real-world evidence data system in the UK. Shares in the company soared in response to the agreement which will see Emerald design and deliver...

on 11/8/20

2 min read